ABSTRACT
This conclusion presents some closing thoughts on the key concepts discussed in the preceding chapters of this book. The book explains the key factors to consider when launching and guiding a company through the early stages of therapeutic development in the biotech industry. It encourages entrepreneurs to develop their own business model that will help them to find mindful and rational ways of leading their business to success. The book helps them avoid the more common mistakes seen individually and collectively as consultants and advisors in the industry. Recent surveys suggest that investors have become wary of investing in biotechnology and life science companies. The Milestone Bridge helps to visualize the company's business model. The business model is the comprehensive set of decisions that defines how to execute the strategy. Day by day, companies makes decisions that may affect focus, locus, and modus.
